Explore the Agenda

8:00 am Check-In & Coffee

8:50 am Chair’s Opening Remarks

Senior Associate Scientist, Stylus Medicine

9:00 am Industry Leader’s Fireside Chat: The Next Decade of LNP Characterization, Which Analytical Technologies Will Shape the Future of RNA Medicines?

Associate Director,, Takeda Pharmaceutical
Executive Director, , Independent Expert
  • Which analytical technologies are generating the most excitement?
  • What are the biggest characterization gaps today?
  • Are we measuring the right CQAs?
  • How will AI and automation transform analytical development?
  • Which technologies will become standard over the next 5-10 years?

Defining & Measuring Critical Quality Attributes for Lipid Nanoparticles

9:30 am Control LNP Variability by Applying Early Developability & Characterization Strategies Using Advanced Analytical Techniques

Senior Scientist II, Abbvie
  • Identify sources of variability during early formulation and process screening, reduce risk of downstream inconsistency
  • Apply advanced characterization techniques to link particle attributes to encapsulation efficiency and performance
  • Establish robust process understanding early, define critical parameters, improve reproducibility and scalability
  • Integrate developability assessments into early workflows, prevent late-stage failures and rework

10:00 am Speed Networking & Morning Break

As the LNP Community unites, this session will provide valuable networking time with your peers, enabling you to forge new and lasting connections and gain unfiltered insight to discuss your challenges.

11:00 am Roundtable Discussion: Establish Predictive CQAs Through Advanced Characterization & Heterogeneity Analysis

Sr Director, Beam Therapeutics Inc.
  • Moving beyond particle size and reassessing CQAs for next-generation LNP therapeutics
  • How should CQA strategies differ between discovery, IND-enabling, and commercial stages?
  • How do we connect analytical attributes to potency, safety, and efficacy?

11:30 am Quantitative cryo-EM LNP analysis: From structure to decisions

Co-Founder & Managing Director, ATEM Structural Discovery
  • Our automated, AI-based analysis of thousands of particles per sample turns cryo-EM images into quantitative measurements of LNP size, shape and morphology with high accuracy and precision
  • Findings from four case studies link LNP structure to encapsulation, stability and in vivo expression. Smaller, rounder, solid-core-rich LNPs perform best
  • We are working on standardizing studies for all stages of LNP development, with a focus on easy interpretation, as well as developing new capabilities, such as surface moiety density characterization, improved shape and morphology characterization, sample fingerprinting and full/empty characterization

12:00 pm Panel Discussion: Have We Defined the Right Critical Quality Attributes (CQAs) for LNPs?

Principal Scientist, Chemistry, Manufacturing, Controls, Analytical Development,, Stylus Medicine
Scientist, GT Biosciences
  • If you could only release an LNP product with five assays, what would they be?
  • What are the most over-measured attributes in LNP development today?
  • Should every measured attribute eventually be linked to biological function?

12:30 pm Lunch Break & Networking

Advanced Characterization Methods to Better Understand LNP Structure, Heterogeneity & Particle Populations

1:30 pm Single Particle Analysis of Complex LNPs

Field Application Scientist, Nano FCM
  • Discuss the principles and advantages of single particle analysis for LNP formulations
  • Demonstrate the applicability of the technology to quantifying loading of LNPs and targeting of LNPs both in percent of modified particles and amount of modification per particle
  • Address key regulatory concerns around novel, complex therapeutics

1:40 pm Advancing Structural & Analytical Understanding of Lipid Nanoparticles: From SAXS Method Development to Cross-Functional Standardization

Principal Scientist, Merck & Co
  • Applying SAXS and complementary techniques for LNP structural elucidation and conformational assessment
  • Challenges in interpreting ensemble-averaged data in heterogeneous nanoparticle systems
  • Progress toward developing standardized analytical frameworks for LNP characterization

2:10 pm Are We Measuring the Right CQAs? A Super-Resolution Single-Particle Perspective

Staff Scientist, ONI
  • Compare bulk size, PDI and encapsulation efficiency with per-particle size and cargo loading across four ionizable lipid formulations to see where population averages and individual particles diverge
  • Track single-particle size, cargo-positive fraction and ligand presence over storage time to find early changes that bulk measurements do not capture
  • Measure the ligand-positive fraction of tLNPs across formulations by detecting ligand presence on individual particles, rather than inferring it from reagent input or bulk readouts

2:20 pm Leverage High-Throughput & Advanced Structural Analysis to Accelerate LNP Development

Principal Scientist,, Genentech
  • Combine advanced structural characterization with high-throughput workflows to generate deeper insight into LNP architecture, heterogeneity, and particle behavior earlier in development
  • Translate structural data into actionable development decisions by linking particle attributes to formulation performance, manufacturability, and product quality
  • Build scalable analytical strategies that balance detailed characterization with the speed and throughput needed to support modern LNP development

2:50 pm Poster Session & Afternoon Break

This is your opportunity to contribute to the conversation and share your cutting-edge research with this community while discovering exciting work carried out by your peers. To submit a poster, please contact info@hansonwade.com.

Advancing Targeted LNPs Through Smarter Characterization

4:00 pm Quantify Targeting Ligand Conjugation Efficiency & Surface Density

Principal Associate Scientist, Strand Therapeutics Inc.
  • Measure percent conjugated particles versus free particles, determine antibody or peptide density per LNP, assess conjugation uniformity
  • Identify conjugation sites and ligand orientation, understand impact on targeting efficiency, optimize conjugation chemistry
  • Develop potency assays that reflect binder function, correlate to in vivo targeting, predict clinical performance

4:30 pm Using High-Resolution Mass Spectrometry to Characterize Next- Generation Targeted LNPs

Principal Scientist,, ModeX Therapeutics
  • Apply high-resolution mass spectrometry to simultaneously characterize lipid, RNA, antibody, and conjugate components within targeted LNP systems
  • Quantify conjugation efficiency, assess conjugation site specificity, and investigate product-related heterogeneity impacting therapeutic performance
  • Establish comprehensive analytical workflows to support discovery, process development, and CMC readiness for targeted LNP therapeutics

5:00 pm Advanced Methods for Quality & Reproducibility of Targeted LNPs

Scientist II, Novo Nordisk
  • Reveal hidden LNP heterogeneity by combining bulk and single-particle analytics to better understand composition and structure function relationships
  • Improve reproducibility and product control through advanced characterization of coupling efficiency, particle consistency, and key quality attributes
  • Accelerate translation to CMC and QC readiness by integrating high-resolution

5:30 pm Chair’s Closing Remarks

Senior Associate Scientist, Stylus Medicine

5:35 pm End of Conference Day One